Compare companies
Put any US companies we track side by side — SEC-sourced financials, ratios, forensic scores, and our Quality Score. Add up to four. No market price, no paywall.
BridgeBio Pharma, Inc.
| Metric | BridgeBio Pharma, Inc. BBIOHealthcare |
|---|---|
| Quality Score | 56 / 100 |
| Revenue (latest) | $502M |
| Net income (latest) | −$733M |
| Operating margin | −104.2% |
| Net margin | −146.0% |
| Return on equity | 35.1% |
| Return on assets | −78.3% |
| Return on capital (ROCE) | −80.8% |
| Debt / equity | — |
| Revenue growth (YoY) | 126.3% |
| Altman Z″ (distress) | -14.22 |
| Accruals / assets | −30.7% |
Latest reported figures from each company's own SEC filings (XBRL) plus our derived scores. Blank where a line item isn't cleanly tagged — never estimated. Descriptive factors, not advice. Open a company for its full multi-year history.